<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305093</url>
  </required_header>
  <id_info>
    <org_study_id>MN11819</org_study_id>
    <nct_id>NCT04305093</nct_id>
  </id_info>
  <brief_title>Data Mining: Precision Analytical Retrospective Data Correlation</brief_title>
  <official_title>Precision Analytical Retrospective Data Correlation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Precision Analytical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Precision Analytical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data from previously analyzed clinical samples tested by Precision Analytical, Inc. will be
      mined to identify and select samples from patients reporting hormone supplement use. Patient
      demographics (BMI, for example), different therapies and expected changes in hormone levels
      will be analyzed and hormone metabolite patterns will be compared. Samples will be
      deidentified prior to analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have a list of 10 estrogen metabolites, 8 androgen metabolites, two
      progesterone metabolites, 4 cortisol metabolites, free cortisol, six organic acids,
      8-hydroxy-2'-deoxyguanosine (8-OHdG), and melatonin that are measured on patient urine
      samples and cortisol and cortisone on patient saliva samples. The investigators would like to
      both reinforce the validation of the accuracy of these urinary markers and examine how these
      markers associate with patient demographics, symptoms, hormone therapy doses and routes of
      administration.

      This study will involve analysis of existing data from routine clinical care. All data will
      be deidentified and each set of results will be given a study ID number. The key will be held
      by Danielle Martinot and will contain only the original Precision Analytical sample accession
      number and the new study ID (identification). No identifying PHI (Protected Health
      Information) will be accessible to the PI.

      These data will be used to evaluate the following hypotheses: 1) Urinary hormone measures
      accurately reflect expected changes in hormones with regard to circadian rhythm, menstrual
      status, and use of hormonal medications; 2) Urinary metabolites of cortisol will show a
      stronger association with body mass index and symptoms related to cortisol production as
      compared to salivary measures; 3) Urine values of reproductive hormones and organic acids
      will correlate to the dosing of estrogen and androgens more strongly than to progesterone
      creams; 4) 8-OHdG, a measure of oxidative stress, and melatonin will be correlated with age
      and BMI; and 5) Urinary hormone measures will capture age-related changes in hormone
      regulation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Anticipated">November 21, 2021</completion_date>
  <primary_completion_date type="Actual">January 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BMI - weight and height will be combined to report BMI in kg/m2</measure>
    <time_frame>6 months</time_frame>
    <description>Relationship of BMI to cortisol production and clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary hormonal profile including concentrations of estrone, estradiol, estriol, alpha-pregnanediol, and beta-pregnanediol</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of urine estrogen and progesterone metabolites in postmenopausal women receiving hormonal treatment</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">144561</enrollment>
  <condition>Obesity; Endocrine</condition>
  <condition>Hormone Disturbance</condition>
  <arm_group>
    <arm_group_label>Precision Analytical patients</arm_group_label>
    <description>Individuals who had laboratory work completed at Precision Analytical and completed the associated questionnaire on symptoms and comorbidities.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals between the ages of 18 and 85 years with data in the Precision Analytical
        database
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Had testing done at Precision Analytical between 2016 and 2019

        Exclusion Criteria:

          -  Varies by data analysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Mark Newman, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Precision Analytical, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Precision Analytical, Inc</name>
      <address>
        <city>McMinnville</city>
        <state>Oregon</state>
        <zip>97128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Abraham SB, Rubino D, Sinaii N, Ramsey S, Nieman LK. Cortisol, obesity, and the metabolic syndrome: a cross-sectional study of obese subjects and review of the literature. Obesity (Silver Spring). 2013 Jan;21(1):E105-17. doi: 10.1002/oby.20083.</citation>
    <PMID>23505190</PMID>
  </reference>
  <reference>
    <citation>DUNKELMAN SS, FAIRHURST B, PLAGER J, WATERHOUSE C. CORTISOL METABOLISM IN OBESITY. J Clin Endocrinol Metab. 1964 Sep;24:832-41.</citation>
    <PMID>14216471</PMID>
  </reference>
  <reference>
    <citation>Newman M, Pratt SM, Curran DA, Stanczyk FZ. Evaluating urinary estrogen and progesterone metabolites using dried filter paper samples and gas chromatography with tandem mass spectrometry (GC-MS/MS). BMC Chem. 2019 Feb 4;13(1):20. doi: 10.1186/s13065-019-0539-1. eCollection 2019 Dec.</citation>
    <PMID>31384769</PMID>
  </reference>
  <reference>
    <citation>Pasquali R, Cantobelli S, Casimirri F, Capelli M, Bortoluzzi L, Flamia R, Labate AM, Barbara L. The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab. 1993 Aug;77(2):341-6.</citation>
    <PMID>8393881</PMID>
  </reference>
  <reference>
    <citation>Rask E, Olsson T, SÃ¶derberg S, Andrew R, Livingstone DE, Johnson O, Walker BR. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab. 2001 Mar;86(3):1418-21.</citation>
    <PMID>11238541</PMID>
  </reference>
  <reference>
    <citation>Stimson RH, Andersson J, Andrew R, Redhead DN, Karpe F, Hayes PC, Olsson T, Walker BR. Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans. Diabetes. 2009 Jan;58(1):46-53. doi: 10.2337/db08-0969. Epub 2008 Oct 13.</citation>
    <PMID>18852329</PMID>
  </reference>
  <reference>
    <citation>SZENAS P, PATTEE CJ. Studies on adrenocortical function in obesity. J Clin Endocrinol Metab. 1959 Mar;19(3):344-50.</citation>
    <PMID>13631051</PMID>
  </reference>
  <reference>
    <citation>Tomlinson JW, Finney J, Hughes BA, Hughes SV, Stewart PM. Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss. Diabetes. 2008 Jun;57(6):1536-43. doi: 10.2337/db08-0094. Epub 2008 Mar 13.</citation>
    <PMID>18340018</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cortisol</keyword>
  <keyword>Cortisol metabolites</keyword>
  <keyword>Obesity</keyword>
  <keyword>testosterone</keyword>
  <keyword>estradiol</keyword>
  <keyword>Hormone therapy</keyword>
  <keyword>Sleep disturbance</keyword>
  <keyword>Aging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

